The

 

Word

 

Is

Getting

 

Out

 

In the News

 
 

DALCOR PHARMACEUTICALS TO PRESENT AT BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE 2017

LONDON and MONTREAL, April 27, 2017 – DalCor Pharmaceuticals today announced that senior management will present at the Bloom BurtonREAD MORE…

Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Deutsche Bank 42nd Annual Health Care Conference

ROCKVILLE, Md., April 26, 2017 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced thatREAD MORE…

Oncobiologics Secures Additional Funding

CRANBURY, N.J., April 17, 2017 (GLOBE NEWSWIRE) — Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturingREAD MORE…

Puma Biotechnology Announces FDA Advisory Committee to Review Neratinib for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

LOS ANGELES, Calif., April 17, 2017 – Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, today announced that the U.S.READ MORE…

Axovant Sciences Announces Appointment of Dr. David Hung as Chief Executive Officer and Expansion of Board of Directors

BASEL, Switzerland, April 10, 2017 /PRNewswire/ — Axovant Sciences (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia,READ MORE…

Cyclacel Presents Identification of Sensitive Target Indications and Synergistic Drug Combinations for Novel PLK1 Inhibitor CYC140

BERKELEY HEIGHTS, N.J., April 04, 2017 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), today announcedREAD MORE…

Corbus Pharmaceuticals Reports Positive Topline Data Demonstrating Anabasum Reduces Acute Pulmonary Exacerbations and Multiple Inflammatory Biomarkers in Phase 2 Study in Patients with Cystic Fibrosis

NORWORD, MA — (Marketwired) — 03/30/17 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stageREAD MORE…

Corbus Pharmaceuticals to Present Gene Expression Data from Recent Phase 2 Systemic Sclerosis Study Demonstrating JBT-101 Inhibits Inflammation and Fibrosis Pathways

NORWOOD, MA — (Marketwired) — 03/08/17 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stageREAD MORE…

Cyclacel’s CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism of Action, in Research Published in JNCI

BERKELEY HEIGHTS, N.J., March 07, 2017 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (“Cyclacel” or the “Company”), today announcedREAD MORE…

DalCor’s Phase 3 Cardiovascular Trial, dal-GenE, Exceeds Targeted Enrollment Schedule

LONDON and MONTREAL, March 7, 2017 – DalCor Pharmaceuticals today announced it is ahead of the enrollment schedule with theREAD MORE…

Alder BioPharmaceuticals Announces Presentations at 69th Annual American Academy of Neurology Meeting Supporting Development of Eptinezumab for Migraine Prevention

BOTHELL, Wash., March 06, 2017 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics,READ MORE…

Puma Biotechnology to Present at Cowen’s Health Care Conference

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, PresidentREAD MORE…

Biostage to Host Fiscal Year 2016 Update Conference Call

HOLLISTON, Mass., March 2, 2017 /PRNewswire/ — Biostage, Inc. (Nasdaq: BSTG), (“Biostage” or the “Company”), a biotechnology company developing bioengineered organREAD MORE…

Tonix Pharmaceuticals Announces Demonstrated Vaccine Activity in First-Ever Synthesized Chimeric Horsepox Virus

Pre-Clinical Smallpox-Preventing Vaccine Candidate TNX-801 May Qualify for Priority Review Voucher if FDA-Approved Under Provisions in the 21st Century CuresREAD MORE…

Curis to Present at the Cowen and Company 37th Annual Health Care Conference

Curis to Present at the Cowen and Company 37th Annual Health Care Conference (NASDAQ:CRIS) LEXINGTON, Mass., March 01, 2017 (GLOBEREAD MORE…

Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at the Cowen and Company 37th Annual Health Care Conference

TNX-102 SL, a Phase 3 Drug Candidate, Recently Granted Breakthrough Therapy Designation by the US FDA Pivotal Study in Military-RelatedREAD MORE…

Catalyst Pharmaceuticals Supports Rare Disease Day® and Joins Global Movement to Raise Important Awareness for Rare Diseases

CORAL GABLES, Fla., Feb. 27, 2017 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), (Catalyst) a biopharmaceutical company focused on  developing READ MORE…

Auris Medical Receives FDA Fast Track Designation for AM-111 in Acute Sensorineural Hearing Loss

Zug, Switzerland, Feb. 24, 2017 – Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics thatREAD MORE…

Auris Medical and King’s College London Extend Tinnitus Collaboration

– Selection of lead compound for AM-102 program planned for 2017 ZUG, Switzerland, Feb. 22, 2017 (GLOBE NEWSWIRE) — AurisREAD MORE…

Revolutionary Diagnostic SeptiCyte™ LAB Cleared By FDA for Suspected Sepsis Patients

SEATTLE, Feb. 22, 2017 – Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients andREAD MORE…

Corbus Pharmaceuticals to Host Research and Development Day on March 13, 2017

Updates on clinical development of JBT-101 and presentation of new pre-clinical and MOA data; Live video webcast on March 13thREAD MORE…

Alder BioPharmaceuticals to Host Conference Call to Discuss Fourth Quarter and Full Year 2016 Financial and Operating Results

BOTHELL, Wash., Feb. 16, 2017 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics,READ MORE…

Puma Biotechnology to Present at RBC Capital Markets Healthcare Conference

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, PresidentREAD MORE…

Axovant Sciences Announces Dementia Pipeline Updates and Reports Financial Results for the Third Fiscal Quarter and Nine Months Ended December 31, 2016

BASEL, Switzerland, Feb. 14, 2017 /PRNewswire/ — Axovant Sciences (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia,READ MORE…

Axovant Sciences Announces Preliminary Results from Interim Analysis of Phase 2 Study Testing Investigational Drug Nelotanserin in Lewy Body Dementia Patients

— Beneficial treatment effect observed on the pre-specified primary endpoint of Unified Parkinson’s Disease Rating Scale (UPDRS) Parts II +READ MORE…

Alder BioPharmaceuticals to Present at the Leerink Partners 6th Annual Global Healthcare Conference

BOTHELL, Wash., Feb. 09, 2017 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics,READ MORE…

Arrowhead Reports Fiscal 2017 First Quarter Results

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2017 first quarter ended DecemberREAD MORE…

Conatus to Present at BIO CEO & Investor Conference

SAN DIEGO, Feb. 06, 2017 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its scheduled presentation to provide anREAD MORE…

Cyclacel Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference

BERKELEY HEIGHTS, N.J., Feb. 06, 2017 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (“Cyclacel” or the “Company”), a biopharmaceuticalREAD MORE…

Auris Medical Expands Clinical Development Pipeline with Intranasal Betahistine for the Treatment of Meniere’s Disease and Vestibular Vertigo

– Pipeline strengthens with addition of AM-125 as third clinical-stage program – Acquisition of assets related to innovative betahistine productREAD MORE…

Novavax Initiates Phase 2 Safety and Immunogenicity Trial of the RSV F Vaccine in Older Adults

GAITHERSBURG, Md., Jan. 19, 2017 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX) today announced the initiation of a Phase 2 clinicalREAD MORE…

CFI.co announces Pharnext as winner of the Best Life-Sciences IPO France 2016 Award

London (U.K.), Paris (France), January 17, 2017 – Capital Finance International (CFI), a print journal and online resource reporting onREAD MORE…

Q&A: Starbucks gift cards, leaderboards, and the quest to get patients to take their pills

STATNews Rebecca Robbins January 16, 2017 SAN FRANCISCO — The big truck driving around downtown here last week was plasteredREAD MORE…

Corbus Pharmaceuticals Receives Orphan Designation for JBT-101 for the Treatment of Systemic Sclerosis in the European Union

NORWOOD, MA — (Marketwired) — 01/17/17 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stageREAD MORE…

Healthcare Experts Debut New Technology at JPMorgan Healthcare Conference

SAN FRANCISCO (KGO) — Entrepreneurs and health experts from all over the world flocked to San Francisco for the JPREAD MORE…

Curis and Aurigene Extend Exclusivity Period of Immuno-Oncology and Precision Oncology Collaboration

LEXINGTON, Mass., Jan. 09, 2017 (GLOBE NEWSWIRE) — Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

Eutilex to Present at the Biotech Showcase™ 2017 Conference

SEOUL, South Korea, Jan. 6, 2017 /PRNewswire/ — Eutilex Co. Ltd., today announced that the company will present at the 9thREAD MORE…

RG7916 Granted Orphan Drug Designation in the U.S. for the Treatment of Spinal Muscular Atrophy

SOUTH PLAINFIELD, N.J., Jan. 6, 2017 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and DrugREAD MORE…

Puma Biotechnology Expands Cohort in Phase II SUMMIT Trial of PB272 in HER2 Mutation-Positive Cancer Patients

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, has expanded the fourth cohort from its Phase II SUMMITREAD MORE…

Novavax to Present at the 35th Annual J.P. Morgan Healthcare Conference

GAITHERSBURG, Md., Jan. 05, 2017 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX) today announced that management will present at the 35thREAD MORE…

Pharnext to Attend January Investor Conferences

Paris, January 4, 2017 – Pharnext SA (FR00111911287 – ALPHA), a French biopharmaceutical company developing an advanced portfolio of productsREAD MORE…

Alder BioPharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference

BOTHELL, Wash., Jan. 02, 2017 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics,READ MORE…

Passage of the 21st Century Cures Act and its Potential Implications on Biodefense

SAN DIEGO, Dec. 21, 2016 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following note authored by itsREAD MORE…

Pharnext Completes Patient Enrollment in International Pivotal Phase 3 Trial of PXT3003 for Charcot-Marie-Tooth Disease Type 1A

Paris, December 20th , 2016 – Pharnext SA (FR00111911287 – ALPHA), a French biopharmaceutical company developing an advanced portfolio ofREAD MORE…

Conatus Announces Exclusive Worldwide Option, Collaboration and License Agreement Covering Development and Commercialization of Emricasan

SAN DIEGO, Dec. 19, 2016 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced it has entered into an exclusiveREAD MORE…

Aethlon Announces Initiation of Sepsis-Related Virus Study

SAN DIEGO, Dec. 15, 2016 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that it has initiated a researchREAD MORE…

Eutilex Completes $18 Million Series A Financing to Advance Immuno-Oncology Programs

SEOUL, South Korea, Dec. 8, 2016 /PRNewswire/ — Eutilex Co. Ltd. today announced that it has completed a $21 billionREAD MORE…

Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2016 San Antonio Breast Cancer Symposium

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that interim results from a Phase II clinical trialREAD MORE…

Corbus Pharmaceuticals Announces NASDAQ Closing Bell Ceremony

NORWOOD, MA — (Marketwired) — 12/05/16 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stageREAD MORE…

Cyclacel’s Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential in Esophageal Cancer and Acute Leukemia

BERKELEY HEIGHTS, N.J., Dec. 01, 2016 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (“Cyclacel” or the “Company”), a biopharmaceuticalREAD MORE…

Novavax to Participate in the Citi 2016 Global Healthcare Conference

GAITHERSBURG, Md., Nov. 30, 2016 (GLOBE NEWSWIRE) — Novavax, Inc., (Nasdaq:NVAX) today announced the Company will participate in the CitiREAD MORE…

Cerecor Reports Top-Line Data from CERC-301 Phase 2 Study for Major Depressive Disorder

CERC-301 misses primary endpoint but the 20 mg dose shows clinically meaningful efficacy signals at Day 2; Management to HoldREAD MORE…

Clinical Data for BackBeat Medical’s Programmable Hypertension Control Therapy to Be Presented at ICI Meeting 2016

NEW HOPE, Pa., Nov. 29, 2016 /PRNewswire/ — BackBeat Medical Inc., a medical technology company developing novel cardiac stimulation-based therapies forREAD MORE…

Corbus Pharmaceuticals Commences One-Year Open-Label Extension to its Ongoing Phase 2 Study of Resunab (JBT-101) for Skin-Predominant Dermatomyositis

NORWOOD, MA — (Marketwired) — 11/29/16 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stageREAD MORE…

Alder BioPharmaceuticals Initiates PROMISE 2 Pivotal Trial of Eptinezumab for the Prevention of Migraine

BOTHELL, Wash., Nov. 28, 2016 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics,READ MORE…

Innocoll Holdings plc Announces Third Quarter 2016 Financial and Operating Results and Provides Corporate Update

ATHLONE, Ireland, Nov. 22, 2016 (GLOBE NEWSWIRE) — Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical company with late stageREAD MORE…

Catalyst Pharmaceuticals to Participate in the 28th Annual Piper Jaffray Healthcare Conference

CORAL GABLES, Fla., Nov. 21, 2016 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing andREAD MORE…

New Jersey Technology Council Honored Chromocell Corporation at the 2016 Awards Celebration

NORTH BRUNSWICK, N.J., Nov. 18, 2016 /PRNewswire/ — New Jersey Technology Council (NJTC) has honored Chromocell Corporation along with the region’sREAD MORE…

Pharnext Announces that the Data Safety Monitoring Board Recommends Continuing the Ongoing Phase 3 Trial of PXT3003 for Charcot-Marie-Tooth Disease Type 1A

Paris, November 17, 2016 – Pharnext SA (FR00111911287 – ALPHA), a French biopharmaceutical company developing an advanced portfolio of productsREAD MORE…

Pharmaceutical Companies Lose $637 Billion in Revenue Annually Due to Medication Nonadherence

NORWALK, Conn., Nov. 16, 2016 /PRNewswire/ — HealthPrize Technologies today announced the publication of an update to a research paperREAD MORE…

International Stem Cell Corporation Announces Operating Results for the Three and Nine-months ended September 30, 2016

CARLSBAD, Calif., Nov. 16, 2016 (GLOBE NEWSWIRE) — International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) (“ISCO” or “the Company”), a California-basedREAD MORE…

Cyclacel Pharmaceuticals Reports 3rd Quarter 2016 Financial Results

BERKELEY HEIGHTS, N.J., Nov. 14, 2016 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (“Cyclacel” or the “Company”), a biopharmaceuticalREAD MORE…

Arrowhead Pharmaceuticals Presents New Data on ARC-F12 and ARC-LPA Using DPCsqTM Subcutaneous RNAi Delivery Vehicle

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today delivered oral presentations on ARC-LPA, its preclinical development program targeting lipoproteinREAD MORE…

Oncobiologics Announces Presentation Of Final Data From Phase 1 Clinical Study Of ONS-3010 (HUMIRA® Biosimilar)

CRANBURY, N.J., Nov. 14, 2016 (GLOBE NEWSWIRE) — Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturingREAD MORE…

Innocoll Holdings plc to Present at the Stifel 2016 Healthcare Conference

ATHLONE, Ireland, Nov. 14, 2016 (GLOBE NEWSWIRE) — Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical and medical device companyREAD MORE…

Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting

SAN DIEGO , Nov. 14, 2016 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today the presentation of four postersREAD MORE…

Arrowhead Pharmaceuticals Presents New Data on ARC-AAT

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) delivered a poster presentation with Phase 1 clinical data and an oralREAD MORE…

Curis Announces Appointment of Lori A. Kunkel, M.D. to Board of Directors

LEXINGTON, Mass., Nov. 14, 2016 (GLOBE NEWSWIRE) — Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

Corbus Pharmaceuticals Reports Positive Topline Results Showing Clear Signal of Clinical Benefit with Resunab (JBT-101) in Phase 2 Study in Systemic Sclerosis

NORWOOD, MA — (Marketwired) — 11/14/16 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stageREAD MORE…

Gaumard to Show New Touch-Screen Wireless Simulation Interface at AHA Scientific Sessions

MIAMI, Nov. 11, 2016 /PRNewswire/ — Gaumard® Scientific Company will demonstrate how it is transforming CPR training with value-priced simulators and skillsREAD MORE…

DalCor Announces Data to be Presented at the American Heart Association Scientific Sessions 2016 in New Orleans

LONDON, Nov. 10, 2016 /PRNewswire/ — DalCor Pharmaceuticals today announced the key investigator in dalcetrapib trials, Jean-Claude Tardif, C.M., M.D., FRCPC,READ MORE…

International Stem Cell Corporation to Present Results of Neural Stem Cell Transplantation for Parkinson’s Disease at the Neuroscience 2016 Conference

CARLSBAD, Calif., Nov. 10, 2016 (GLOBE NEWSWIRE) — International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developingREAD MORE…

Auris Medical Provides Business Update and Reports Third Quarter 2016 Financial Results

ZUG, Switzerland, Nov. 10, 2016 (GLOBE NEWSWIRE) — Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeuticsREAD MORE…

Novavax Reports Third Quarter 2016 Financial Results

GAITHERSBURG, Md., Nov. 09, 2016 (GLOBE NEWSWIRE) — Novavax, Inc., (Nasdaq:NVAX) today announced its financial results for the third quarterREAD MORE…

Catalyst Pharmaceuticals Announces Third Quarter 2016 Financial Results and Provides Corporate Update

Catalyst Pharmaceuticals Announces Third Quarter 2016 Financial Results and Provides Corporate Update Company to Host Quarterly Conference Call at 8:30READ MORE…

Curis Presents Early Clinical Pharmacokinetic and Biomarker Data from CA-170’s Phase 1 Trial at the SITC 2016 Conference

LEXINGTON, Mass., Nov. 09, 2016 (GLOBE NEWSWIRE) — Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

Arrowhead Pharmaceuticals Provides Update on Heparc-2004 Study

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is providing an update on its Heparc-2004 clinical study of ARC-520, itsREAD MORE…

Conatus Pharmaceuticals to Present at Stifel 2016 Healthcare Conference

SAN DIEGO, Nov. 09, 2016 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its scheduled presentation to provide anREAD MORE…

Conatus Pharmaceuticals Reports Third Quarter 2016 Financial Results and Program Updates

SAN DIEGO, Nov. 08, 2016 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development andREAD MORE…

Axovant Sciences Announces Dementia Pipeline Updates and Reports Financial Results for the Second Fiscal Quarter and First Half Ended September 30, 2016

HAMILTON, Bermuda, Nov. 7, 2016 /PRNewswire/ — Axovant Sciences Ltd. (NYSE:  AXON), a leading clinical-stage biopharmaceutical company focused on theREAD MORE…

Discovery of Cerecor Drug Candidate CERC-611 (LY3130481) Published in Nature Medicine

TARP ɣ-8 selectivity may lead to enhanced antiseizure therapy BALTIMORE, MD — (Marketwired) — 11/07/16 — Cerecor, Inc. (NASDAQ: CERC),READ MORE…

Cyclacel Pharmaceuticals to Release Third Quarter 2016 Financial Results

BERKELEY HEIGHTS, N.J., Nov. 07, 2016 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (“Cyclacel” or the “Company”), a biopharmaceuticalREAD MORE…

Eutilex Names Agustin de la Calle Chief Business Officer

SEOUL, South Korea, Nov. 7, 2016 /PRNewswire/ — Eutilex Co. Ltd. today announced that it has appointed Agustin de la Calle,READ MORE…

Auris Medical to Announce Third Quarter 2016 Financial Results and Host Conference Call on Thursday, November 10, 2016

Basel, Switzerland, Nov. 03, 2016 (GLOBE NEWSWIRE) — Zug, Switzerland, Nov. 3, 2016 – Auris Medical Holding AG (NASDAQ: EARS),READ MORE…

Conatus Initiates Phase 2b ENCORE-PH Clinical Trial of Emricasan in Patients with NASH Cirrhosis

SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced the initiation of ENCORE-PH (PH forREAD MORE…

Curis Reports Third Quarter 2016 Financial Results

LEXINGTON, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) — Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

Novavax to Host Conference Call to Discuss Third Quarter Financial Results on November 9, 2016

GAITHERSBURG, Md., Nov. 02, 2016 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX) today announced it will host an Investor and AnalystREAD MORE…

Conatus Pharmaceuticals to Report Third Quarter 2016 Financial Results

SAN DIEGO, Nov. 01, 2016 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development andREAD MORE…

Catalyst Pharmaceuticals to Hold Third Quarter Financial Results Conference Call and Webcast on Thursday, November 10th, 2016

CORAL GABLES, Fla., Nov. 01, 2016 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializingREAD MORE…

Alder BioPharmaceuticals to Present at Two Upcoming November Conferences

BOTHELL, Wash., Nov. 01, 2016 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics,READ MORE…

Arrowhead Pharmaceuticals to Present at Upcoming Conferences

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) will make presentations at the following upcoming events: The 25th Annual CreditREAD MORE…

Puma Biotechnology to Present at Credit Suisse Healthcare Conference

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, PresidentREAD MORE…

BackBeat Medical Clinical Data Presented at TCT 2016 Show Continued Reduction in Blood Pressure Over One Year with Cardiac Pacing-Based Hypertension Treatment

NEW HOPE, Pa., Oct. 31, 2016 /PRNewswire/ — BackBeat Medical Inc. today announced the presentation of data demonstrating a continued significantREAD MORE…

Catalyst Pharmaceuticals Receives Special Protocol Assessment (SPA) from the FDA for Second Phase 3 Clinical Trial Evaluating Firdapse for the Treatment of LEMS

CORAL GABLES, Fla., Oct. 31, 2016 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing andREAD MORE…

Opiant Pharmaceuticals, Inc. Licenses Heroin Vaccine From Walter Reed Army Institute of Research and National Institute on Drug Abuse

SANTA MONICA, Calif., Oct. 28, 2016 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacologicalREAD MORE…

Sucampo Announces Third Quarter 2016 Earnings Call

ROCKVILLE, Md., Oct. 28, 2016 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced thatREAD MORE…

Alder BioPharmaceuticals Announces Third Quarter 2016 Financial and Operating Results

BOTHELL, Wash., Oct. 27, 2016 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics,READ MORE…

Curis to Release Third Quarter 2016 Financial Results and Hold Conference Call on November 3, 2016

LEXINGTON, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) — Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

Clinical Data for BackBeat Medical’s Programmable Hypertension Control Therapy to Be Presented at TCT 2016

NEW HOPE, Pa., Oct. 26, 2016 /PRNewswire/ — BackBeat Medical Inc. today announced that clinical data for the company’s patented ProgrammableREAD MORE…

Arrowhead Pharmaceuticals to Present Data on ARC-AAT at The Liver Meeting(R)

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will make two presentations on ARC-AAT, the company’sREAD MORE…

Alder BioPharmaceuticals to Host Conference Call to Discuss Third Quarter 2016 Financial and Operating Results

BOTHELL, Wash., Oct. 20, 2016 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics,READ MORE…

Puma Biotechnology Prices Public Offering of Common Stock

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the pricing of an underwritten public offering of 3,750,000READ MORE…

Clinical Data Demonstrate Effectiveness of MOTUS GI™’s Pure-Vu™ System in Achieving Adequate Bowel Prep in Poorly Prepped Colonoscopy Patients

TIRAT CARMEL, Israel, Oct. 18, 2016 – MOTUS GI, a medical device company dedicated to improving colonoscopy outcomes and experiences,READ MORE…

The Medicines Company Announces Positive Top-Line Results from Day 90 Interim Analysis in Ongoing ORION-1 Phase 2 Study of PCSK9si

PARSIPPANY, N.J.–(BUSINESS WIRE)–The Medicines Company (NASDAQ:MDCO) today announced top-line results from the interim analysis with Day 90 follow-up for allREAD MORE…

Corbus Pharmaceuticals Receives Orphan Designation for Resunab for the Treatment of Cystic Fibrosis in the European Union

Company on track to complete Phase 2 study in cystic fibrosis in 2016; Phase 2 topline results expected Q1 2017READ MORE…

International Stem Cell Corporation Announces Positive Efficacy Results in Traumatic Brain Injury

CARLSBAD, Calif., Oct. 18, 2016 (GLOBE NEWSWIRE) — International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developingREAD MORE…

Quark Pharmaceuticals Launches EyeActNow.com to Promote NAION Study

FREMONT, Calif., Oct. 14, 2016 /PRNewswire/ — Quark Pharmaceuticals, Inc. today announced the launch of www.EyeActNow.com to promote public awareness andREAD MORE…

Cynapsus Therapeutics Securityholders Approve the Plan of Arrangement with Sunovion Pharmaceuticals

TORONTO, Oct. 13, 2016 (GLOBE NEWSWIRE) — Cynapsus Therapeutics Inc. (“Cynapsus”) (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system pharmaceutical companyREAD MORE…

Catalyst Pharmaceuticals to Present at 15th Annual BIO Investor Forum

CORAL GABLES, Fla., Oct. 13, 2016 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializingREAD MORE…

The Medicines Company to Present Data from its Investigational Anesthetic MDCO-700 at the ANESTHESIOLOGY® 2016 Annual Meeting and the ISAP 25th Annual Meeting

PARSIPPANY, N.J.–(BUSINESS WIRE)–Oct. 13, 2016– The Medicines Company (NASDAQ:MDCO) today announced that five abstracts with data from its investigational anesthetic MDCO-700READ MORE…

Corbus Pharmaceuticals Announces Completion of Phase 2 Study of Resunab for Systemic Sclerosis

NORWOOD, MA — (Marketwired) — 10/13/16 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stageREAD MORE…

Chromocell and Astellas Announce FDA Fast Track Designation and First Subject Dosing with Lead Candidate CC8464/ASP1807 for the Management of Neuropathic Pain Associated with iSFN

NORTH BRUNSWICK, N.J. and TOKYO, Oct. 12, 2016 /PRNewswire/ — Chromocell Corporation and Astellas Pharma Inc. announced today that theREAD MORE…

Symic Bio to Present at the 15​ th​ Annual BIO Investor Forum

SAN FRANCISCO, Oct. 11, 2016 – Symic Bio, a clinical stage biopharmaceutical company developing a new category of therapeutics focusedREAD MORE…

Alder BioPharmaceuticals Promotes Larry Benedict to Executive Vice President of Finance and Principal Accounting Officer

BOTHELL, Wash., Oct. 11, 2016 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage company developing monoclonal antibody therapeutics, todayREAD MORE…

Auris Medical Provides Update on Development of Keyzilen for the Treatment of Acute Inner Ear Tinnitus

ZUG, Switzerland, Oct. 11, 2016 (GLOBE NEWSWIRE) — Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developingREAD MORE…

Curis Expands Oncology Pipeline with an Oral Small Molecule PD-L1/TIM-3 Immune Checkpoint Antagonist

LEXINGTON, Mass., Oct. 11, 2016 (GLOBE NEWSWIRE) — Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

PTC Therapeutics Announces New Analyses that Support the Potential Benefit of Ataluren in Preserving Lung Function in Non-Ambulatory Nonsense Mutation Duchenne Muscular Dystrophy Patients

SOUTH PLAINFIELD, N.J., Oct. 6, 2016 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced new data supporting the potential benefitREAD MORE…

Arrowhead and Spring Bank Announce Clinical Collaboration for ARC-520 and SB 9200 in Chronic Hepatitis B

PASADENA, Calif. & HOPKINTON, Mass.–(BUSINESS WIRE)– Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) and Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stageREAD MORE…

The Medicines Company Provides Progress Update on Ongoing ORION-1 Study of PCSK9si

PARSIPPANY, N.J.–(BUSINESS WIRE)–Oct. 5, 2016– The Medicines Company (NASDAQ:MDCO) today provided a progress update on the ongoing ORION-1 study ofREAD MORE…

International Stem Cell Corporation Publishes Results of Safety Studies Conducted in Support of the First Human Pluripotent Stem Cell Based Therapy for Parkinson’s Disease

CARLSBAD, Calif., Oct. 05, 2016 (GLOBE NEWSWIRE) — International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developingREAD MORE…

Pharnext Announces Support of the First Patient-Centered Charcot-MarieTooth Summit Organized by the Hereditary Neuropathy Foundation

Paris, Oct. 4, 2016 – Pharnext (ISIN FR00111911287), a French biopharmaceutical company developing an advanced portfolio of products in theREAD MORE…

Conatus Pharmaceuticals Announces Acceptance of Emricasan Abstracts for AASLD Annual Meeting

Emricasan Improves Liver Function in Cirrhosis Patients with NASH and/or Elevated MELD Scores Emricasan Improves Hepatic Blood Flow, Portal Hypertension,READ MORE…

ISS Recommends Cynapsus Therapeutics Securityholders Vote for the Plan of Arrangement

TORONTO, Sept. 28, 2016 (GLOBE NEWSWIRE) — Cynapsus Therapeutics Inc. (“Cynapsus”) (NASDAQ:CYNA) (TSX:CTH) is pleased to announce today that InstitutionalREAD MORE…

Amgen and Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations

THOUSAND OAKS, Calif. and PASADENA, Calif. (Sept. 29, 2016) — Amgen (NASDAQ: AMGN) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) todayREAD MORE…

Doctors Say Yearly Memory Evaluations are Critical to Early Diagnosis, Effective Treatment of Alzheimer’s Disease

NEW YORK, Sept. 21, 2016 /PRNewswire/ — Memory evaluations are critical to the early diagnosis and effective treatment of peopleREAD MORE…

Alder BioPharmaceuticals Appoints Nancy L. Boman, M.D., Ph.D., Senior Vice President of Regulatory Affairs and Pharmacovigilance

BOTHELL, Wash., Sept. 21, 2016 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics,READ MORE…

Corbus Pharmaceuticals to Present at the Jefferies Cystic Fibrosis Summit

NORWOOD, MA–(Marketwired – September 19, 2016) – Corbus Pharmaceuticals Holdings, Inc.(NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drugREAD MORE…

Pharnext Confirms its Continuous Support of the Hereditary Neuropathy Foundation to Increase Global Awareness of Charcot-Marie-Tooth Disease

Paris, September 15, 2016 – Pharnext (ISIN FR00111911287), a French biopharmaceutical company developing an advanced portfolio of products in theREAD MORE…

Alder Presents Positive ALD403 Clinical Data at European Headache and Migraine Trust International Congress

BOTHELL, Wash., Sept. 15, 2016 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics,READ MORE…

Auris Medical Announces AAO-HNSF Annual Meeting Activities

ZUG, Switzerland, Sept. 13, 2016 (GLOBE NEWSWIRE) — Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics thatREAD MORE…

Corbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Resunab for the Treatment of Cystic Fibrosis

NORWOOD, MA — (Marketwired) — 09/12/16 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stageREAD MORE…

Auris Medical Achieves Midpoint for Enrollment in Phase 3 Trial of AM-111 in Sudden Deafness

ZUG, Switzerland, Sept. 9, 2016 (GLOBE NEWSWIRE) — Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developingREAD MORE…

PTC Therapeutics Recognizes World Duchenne Awareness Day by Announcing Winners of Global Duchenne Muscular Dystrophy Patient Group Awards and Expanding Disease State Awareness Website

SOUTH PLAINFIELD, N.J., Sept. 7, 2016 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) is pleased to announce the recipients of theREAD MORE…

Innocoll Holdings plc to Present at the Morgan Stanley Global Healthcare Conference

ATHLONE, Ireland, Sept. 07, 2016 (GLOBE NEWSWIRE) — Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical and medical device companyREAD MORE…

Novavax to Host 4th Annual Investor and Analyst Meeting

GAITHERSBURG, Md., Sept. 07, 2016 (GLOBE NEWSWIRE) — Novavax, Inc., (Nasdaq:NVAX) today announced it will host its 4th annual InvestorREAD MORE…

Catalyst Pharmaceuticals to Present at Rodman & Renshaw’s 18th Annual Global Investment Conference

CORAL GABLES, Fla., Sept. 08, 2016 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developingREAD MORE…

Alder BioPharmaceuticals Appoints Elisabeth A. Sandoval as Chief Commercial Officer

Addition to Leadership Team Expands Commercialization Focus and Supports Continued Successful Advancement of ALD403 for Migraine Prevention BOTHELL, Wash., Sept.READ MORE…

Arrowhead Pharmaceuticals Initiates Phase 2 Study of ARC-AAT

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it initiated a Phase 2 clinical study of ARC-AAT,READ MORE…

Cyclacel’s CYC065 Demonstrates Promising Activity in MYCN-Addicted Neuroblastoma in Preclinical Data Presented at Childhood Cancer 2016

Data support CYC065 as potential treatment for MYCN amplified/overexpressed neuroblastoma BERKELEY HEIGHTS, N.J., Sept. 06, 2016 (GLOBE NEWSWIRE) — CyclacelREAD MORE…

Pharnext’s PXT3003 Featured in Multiple Presentations at the 6th International Charcot-Marie-Tooth and Related Neuropathy Consortium (CMTR) Meeting

Paris, September 1, 2016 – Pharnext (ISIN FR00111911287), a French biopharmaceutical company developing an advanced portfolio of products in theREAD MORE…

Arrowhead Pharmaceuticals to Present at Upcoming September Conferences

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the company will make presentations at the following upcomingREAD MORE…

Axovant Sciences to Present at the Baird 2016 Global Healthcare Conference

HAMILTON, Bermuda, Aug. 31, 2016 /PRNewswire/ — Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment ofREAD MORE…

Oncobiologics To Present At BioCentury’s NewsMakers In The Biotech Industry Conference

CRANBURY, N.J., Aug. 31, 2016 (GLOBE NEWSWIRE) — Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturingREAD MORE…

Alder BioPharmaceuticals to Present at Two Upcoming September Healthcare Conferences

BOTHELL, Wash., Aug. 31, 2016 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics,READ MORE…

Symic to Present at the 23rd Annual BioCentury NewsMakers in the Biotech Industry Conference

SAN FRANCISCO, Aug. 29, 2016 – Symic, a clinical stage biotherapeutics company developing therapies inspired by naturally occurring molecules ofREAD MORE…

Cynapsus Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson’s Disease

AUGUST 29, 2016 Company provides timing updates TORONTO, Aug. 29, 2016 (GLOBE NEWSWIRE) — Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH), todayREAD MORE…

DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial

Sites open in Europe and New Zealand Enrollment on schedule in trial of dalcetrapib in genetically distinct patients with acuteREAD MORE…

Puma Biotechnology Announces European Medicines Agency Validation of Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the Marketing Authorization Application (MAA) for neratinib hasREAD MORE…

HealthPrize teams up with Walgreens to get patients to follow prescriptions

Westfair Online   HealthPrize teams up with Walgreens to get patients to follow prescriptions http://westfaironline.com/81301/healthprize-teams-up-with-walgreens-to-get-patients-to-follow-prescriptions/   Bob Rozycki August 16,READ MORE…

Walgreens hopes gamelike program will make taking meds easier

The Chicago Tribune   Walgreens hopes gamelike program will make taking meds easier http://www.chicagotribune.com/business/ct-walgreens-games-drugs-0816-biz-20160815-story.html   Lisa Schencker August 16, 2016READ MORE…

Walgreens to offer Healthprize’s medication adherence tool to select patients online

MobiHealthNews   Walgreens to offer Healthprize’s medication adherence tool to select patients online http://mobihealthnews.com/content/walgreens-offer-healthprizes-medication-adherence-tool-select-patients-online   Heather Mack August 16, 2016READ MORE…

Five things for pharma marketers to know: Tuesday, August 16, 2016

Medical Marketing & Media   Five things for pharma marketers to know: Tuesday, August 16, 2016 http://www.mmm-online.com/roundup/five-things-for-pharma-marketers-to-know-tuesday-august-16-2016/article/516300/   Virginia LauREAD MORE…

Walgreens partners for game-based drug adherence platform

Fierce Biotech   Walgreens partners for game-based drug adherence platform http://www.fiercebiotech.com/medical-devices/walgreens-to-market-healthprize-s-game-based-drug-adherence-platform   Amirah Al Idrus August 16, 2016    READ MORE…

Walgreens wants you to take your pills

Crain’s Business Chicago   Walgreens wants you to take your pills http://www.chicagobusiness.com/article/20160816/NEWS03/160819917/walgreens-launches-gamified-patient-engagement-app-to-boost-drug   Duncan Moore Jr. August 16, 2016  READ MORE…

Walgreens hopes gamelike program will make taking meds easier

Business Walgreens hopes gamelike program will make taking meds easier Walgreens at State and Randolph Streets in Chicago on JulyREAD MORE…

Patient, wife share their story of how brain disorder study changed their lives

ORLANDO, Fla. – A Central Florida doctor is conducting the first-ever clinical trial in Orlando for people with the brainREAD MORE…

Conatus Pharmaceuticals Reports Second Quarter 2016 Financial Results and Program Updates

SAN DIEGO, Aug. 03, 2016 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development andREAD MORE…

Accera Appoints C. Evan Ballantyne as Chief Financial Officer

Accera Appoints C. Evan Ballantyne as Chief Financial Officer BOULDER, Colo., Aug. 2, 2016 – Accera, Inc., a clinical-stage biotechnologyREAD MORE…

Pharnext Announces the Appointment of René Goedkoop as Chief Medical Officer and François Chamoun as General Counsel

Paris, July 26, 2016 – Pharnext (ISIN FR00111911287), a French biopharmaceutical company developing an advanced portfolio of products in theREAD MORE…

Alder BioPharmaceuticals to Host Conference Call to Discuss Second Quarter 2016 Financial and Operating Results

BOTHELL, Wash., July 19, 2016 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics,READ MORE…

DalCor’s Dalcetrapib Demonstrates Genotype-Dependent Effects on Cholesterol Efflux and Inflammation in Data Published by The Montreal Heart Institute in Circulation Cardiovascular Genetics

Effects on C-reactive protein and cholesterol efflux support dalcetrapib benefits on cardiovascular outcomes in patients with AA genotype of ADCY9READ MORE…

Sucampo Provides Update on Cobiprostone Development Program

ROCKVILLE, Md., July 11, 2016 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced theREAD MORE…

Arrowhead Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that president and chief executive officer Christopher Anzalone, Ph.D., willREAD MORE…

Cynapsus Therapeutics Enrolls Last Patient in Pivotal Phase 3 Efficacy Trial of APL-130277 to Treat OFF Episodes in Patients with Parkinson’s Disease

TORONTO – June 30, 2016 – Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH), a specialty central nervous system (CNS) pharmaceuticalREAD MORE…

Symic Appoints Carolyn Bertozzi, Ph.D., to Scientific Advisory Board

SAN FRANCISCO, June 28, 2016 – Symic, a clinical stage biotherapeutics company developing novel compounds that target and affect theREAD MORE…

Corbus Pharmaceuticals Announces Last Patient Enrolled in Phase 2 Study of Resunab for Systemic Sclerosis

NORWOOD, MA — (Marketwired) — 06/16/16 — RELATED LINKS PDF Release PDF Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” orREAD MORE…

Cyclacel Regains Compliance With Nasdaq Continued Listing Requirements

BERKELEY HEIGHTS, N.J., June 16, 2016 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a biopharmaceuticalREAD MORE…

Alder BioPharmaceuticals Appoints Roger Cady, M.D., Vice President of Neurology

BOTHELL, Wash., June 06, 2016 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics,READ MORE…

U.S. FDA Grants Fast Track Designation to Novavax’ RSV F Vaccine for Older Adults

(GLOBE NEWSWIRE via COMTEX) —  GAITHERSBURG, Md., May 25, 2016 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine companyREAD MORE…

Puma Biotechnology Announces Publication of Neratinib Abstract for the 2016 ASCO Annual Meeting

Puma Biotechnology Announces Publication of Neratinib Abstract for the 2016 ASCO Annual Meeting | Puma Biotechnology Investor Center LOS ANGELES–(BUSINESSREAD MORE…

SeptiCyte™ LAB Outperforms Other Parameters for Distinguishing Sepsis in Data Presented at the American Thoracic Society International Conference

SEATTLE, May 18, 2016 — Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced thatREAD MORE…

Immunexpress Announces Presentation at the American Thoracic Society International Conference on the Validation of SeptiCyte™ Lab

SEATTLE, May 11, 2016 — Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announcedREAD MORE…

StemCells, Inc. to Report 12-Month Cohort I Data from its Phase II Pathway Study

StemCells, Inc. – Investor Relations – News Release NEWARK, Calif., May 10, 2016 (GLOBE NEWSWIRE) — StemCells, Inc. (NASDAQ:STEM), aREAD MORE…

Symic to Present at Upcoming May Conferences

Symic to Present at Upcoming May Conferences – Chief Financial Officer Jocelyn Jackson to present at BioEquity Europe 2016 inREAD MORE…

Pharnext Announces the Opening of the First U.S. Study Site for its PLEO-CMT International Pivotal Phase 3 Trial in Charcot-Marie-Tooth Disease Type 1A

PARIS, April 25, 2016 – Pharnext today announced the opening of the first U.S. trial site for its PLEO-CMT pivotalREAD MORE…

Curis and Aurigene Present Preclinical Data from Multiple Programs at AACR Annual Meeting

LEXINGTON, Mass., April 20, 2016 (GLOBE NEWSWIRE) — Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

Puma Biotechnology’s Neratinib Featured in Poster Presentations at the AACR Annual Meeting 2016

Public Company Information: NYSE: PBYI US74587V1070 LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that its drugREAD MORE…

Immunexpress and Academic Medical Center to Collaborate on Development of Sepsis-Related Biomarker Panels

SEATTLE, April 19, 2016 — Immunexpress Inc. today announced an exclusive collaboration with the Academic Medical Center (AMC) at the UniversityREAD MORE…

Retired NFL Players Call for Greater Participation in Alzheimer’s Clinical Trials as Ambassadors at Educational Events, Memory Screenings in U.S., Canada

“Huddle Up for New Alzheimer’s Treatments” Campaign Adds  Joe Rose, Joey Harrington, Ron Pitts, Christian Fauria, Steve Tasker to Line-UpREAD MORE…

Cyclacel’s Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors

Preclinical Data Presented at the AACR 2016 Meeting BERKELEY HEIGHTS, N.J., April 18, 2016 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc.READ MORE…

Arrowhead Research Changes Name to Arrowhead Pharmaceuticals

New website launched at www.arrowheadpharma.com, ticker symbol remains ARWR PASADENA, Calif., April 6, 2016 — Arrowhead Research Corporation (NASDAQ: ARWR)READ MORE…

Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology

— Latest analysis of data presented at the American Society of Hematology’s annual meeting in December, 2015 — — CUDC-907READ MORE…

Arrowhead to Present at Upcoming April Conferences

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the companyREAD MORE…

Association of Bioscience Financial Officers (ABFO) 2016 National Conference Set for May 24-27 in San Diego

EARLY BIRD REGISTRATION ENDS SOON!  Only 8 more days to take advantage of the Early Bird registration. You can saveREAD MORE…

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2015 Financial Results

BERKELEY HEIGHTS, N.J., March 17, 2016 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (“Cyclacel” or the “Company”), a biopharmaceuticalREAD MORE…

Novavax Appoints Bob Darius Senior Vice President, Quality Operations

GAITHERSBURG, Md., March 17, 2016 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, developmentREAD MORE…

BIND Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Announces Shift in Research and Discovery Strategy to Focus on Developing Innovative Medicines Based on ACCURINS(R) Platform

CAMBRIDGE, Mass.–(BUSINESS WIRE)– BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today reportedREAD MORE…

GEN Roundtable Panel Discusses Technologies and Strategies for Product Development

Seven Companies to Watch | Insight & Intelligence™ | GEN In January, San Francisco was the annual venue for theREAD MORE…

Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 28th Annual ROTH Conference

ROCKVILLE, Md., March 09, 2016 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced thatREAD MORE…

BIND Therapeutics to Report Fourth Quarter and Year-End 2015 Financial Results on March 15, 2016

CAMBRIDGE, Mass.–(BUSINESS WIRE)– BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS®,READ MORE…

StemCells, Inc. Announces Pricing of Public Offering to Raise $8.1 Million

StemCells, Inc. – Investor Relations – News Release NEWARK, Calif., March 09, 2016 (GLOBE NEWSWIRE) — StemCells, Inc. (NASDAQ:STEM) todayREAD MORE…

Cynapsus Therapeutics Provides Company Update at Cowen & Co. 36th Annual Health Care Conference

TORONTO, March 7, 2016 – Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH), a specialty central nervous system pharmaceutical company developingREAD MORE…

Corbus Pharmaceuticals Expands Clinical Development of Resunab(TM) With Phase 2 Trial for the Treatment of Systemic Lupus Erythematosus

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, andREAD MORE…

Drug Delivery Roundtable: More than the Pill

One of the more exciting trends in science today is the innovation taking place in the way medicines are administered,READ MORE…

Immunexpress Announces Presentation at the 36th International Symposium on Intensive Care and Emergency Medicine on the Need for an Objective Diagnostic Tool for Systemic Inflammation

Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that data from theREAD MORE…

Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2015 Financial Results

SAN DIEGO, March 02, 2016 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development andREAD MORE…

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016

GAITHERSBURG, Md., Feb. 22, 2016 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, developmentREAD MORE…

Curis to Release Fourth Quarter and Year End 2015 Financial Results and Hold Conference Call on February 29, 2016

LEXINGTON, Mass., Feb. 22, 2016 (GLOBE NEWSWIRE) — Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

Immunexpress Presents Results Indicating the Utility of SeptiCyte™ for the Diagnosis of Sepsis in Critically Ill Children at the 45th Annual Society of Critical Care Medicine Congress

Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced the presentation of dataREAD MORE…

Navidea Biopharmaceuticals Enrolls First Patient in Cervical Cancer Study of Lymphoseek®

DUBLIN, Ohio–(BUSINESS WIRE)–Feb. 11, 2016– Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), today announced that the first patient has been enrolled inREAD MORE…

AZD2811 ACCURINS(R) Data Published in Science Translational Medicine Highlight One of the First Applications of Nanomedicine to Molecularly Targeted Cancer Therapies

BIND Therapeutics and AstraZeneca Publish Preclinical Data Illustrating ACCURINS® Ability to Utilize Proprietary Hydrophobic Ion Pairing to Increase Biodistribution toREAD MORE…

Immunexpress Announces Presentations at the 45th Annual Society of Critical Care Medicine Congress on the Utility of SeptiCyte® Lab

SEATTLE, Feb. 10, 2016 /PRNewswire/ — Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, todayREAD MORE…

Catalyst Pharmaceuticals Announces Initiation of Investigator-Sponsored Study of Firdapse in Patients With MuSK-Antibody Positive Myasthenia Gravis

CORAL GABLES, Fla., Feb. 08, 2016 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies forREAD MORE…

Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2016 Leerink Global Healthcare Conference

ROCKVILLE, Md., Feb. 04, 2016 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced thatREAD MORE…

Alder BioPharmaceuticals to Present at Leerink Partners 5th Annual Global Healthcare Conference

BOTHELL, Wash., Feb. 04, 2016 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeuticsREAD MORE…

Navidea Biopharmaceuticals to Present at 2016 BIO CEO & Investor Conference

DUBLIN, Ohio–(BUSINESS WIRE)–Feb. 4, 2016– Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), announces that Rick Gonzalez, President and Chief Executive Officer,READ MORE…

J.P. Morgan Roundtable: Biotech’s Reputation Tarnished By Drug Pricing Concerns 

Scrip Intelligence 25 January 2016  Mandy Jackson Big pharma companies are used to being criticized for high drug prices, butREAD MORE…

StemCells, Inc. to Participate at the 2016 BIO CEO Conference and Source Capital Group’s 2016 Disruptive Growth and Healthcare Conference

NEWARK, Calif., Jan. 28, 2016 (GLOBE NEWSWIRE) — StemCells, Inc.(Nasdaq:STEM) announced today that management will make presentations on the Company’sREAD MORE…

BIND Therapeutics Provides Enrollment Update for Phase 2 iNSITE 1 and iNSITE 2 Trials with BIND-014

CAMBRIDGE, Mass.–(BUSINESS WIRE)–BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS®, today announced thatREAD MORE…

J.P. Morgan Roundtable: Biotech Executives Expect Capital To Flow Despite Lower Valuations

Scrip Intelligence   J.P. Morgan Roundtable: Biotech Executives Expect Capital To Flow Despite Lower Valuations 24 January 2016  Mandy JacksonREAD MORE…

Novavax to offer $200M in convertible debt; shares down 7% premarket

Novavax Announces Proposed Offering of $200 Million of Convertible Senior Notes Due 2023 – GAITHERSBURG, Md., Jan. 25, 2016 (GLOBE NEWSWIRE)READ MORE…

NFL Broadcaster Solomon Wilcots Teams with MINDSET Study for National Campaign Focused on Alzheimer’s Clinical Research Participation

“Huddle Up for New Alzheimer’s Treatments” Kick-Off Includes Memory Screening with NFL Alumni – Northern California Chapter   Watch theREAD MORE…

Smartwatches to gather data on Parkinson’s patients in Toronto biotech company’s clinical trial

A Toronto-based biotech company is teaming up with the Michael J. Fox Foundation, strapping smartwatches on Parkinson’s patients to test theirREAD MORE…

Spinal Muscular Atrophy Program Advances with Additional Product Candidate Entering Clinical Development

Spinal Muscular Atrophy Program Advances with Additional Product Candidate Entering Clinical Development (NASDAQ:PTCT) SOUTH PLAINFIELD, N.J., Jan. 7, 2016 /PRNewswire/READ MORE…

Biotech tie-up to use smartwatches in Parkinson’s drug trials

By David Crow Financial Times, Health January 7, 2016  Chipmaker Intel and Michael J Fox’s Parkinson’s foundation are teaming upREAD MORE…

Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial

SAN DIEGO, Jan. 05, 2016 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. today announced that the three-month, double-blind, placebo-controlled stage ofREAD MORE…

BIND Therapeutics to Present at Biotech Showcase 2016

CAMBRIDGE, Mass.–(BUSINESS WIRE)– BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS®, todayREAD MORE…

Puma Biotechnology to Present at J.P. Morgan Healthcare Conference

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, PresidentREAD MORE…

Cynapsus Therapeutics Completes Short-Form Amalgamation with Wholly-Owned Subsidiary

TORONTO – Cynapsus Therapeutics Inc., a specialty central nervous system  pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use,READ MORE…

Novavax Initiates Global Pivotal Phase 3 Trial of the RSV F Vaccine to Protect Infants via Maternal Immunization

GAITHERSBURG, Md., Dec. 03, 2015 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, developmentREAD MORE…

Ocata’s Hemangio-derived Mesenchymal Cells Preserve Kidney Function and Extend Lifespan in Preclinical Model of Lupus Nephritis

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of regenerative medicine, reported in Scientific Reports ‒ aREAD MORE…

Symic Secures $25 Million in Series A-2 Financing to Advance Clinical-Stage Biotherapeutics Platform

SAN FRANCISCO, Dec. 1, 2015 /PRNewswire/ — Symic, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellularREAD MORE…

International Stem Cell Corporation Announces Launch Plans for New Nano-Compound Products

CARLSBAD, CA–(Marketwired – December 01, 2015) – International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stemREAD MORE…

Puma Biotechnology Provides Update from Meeting with European Medicines Agency

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that based on its recent meeting with the EuropeanREAD MORE…

Gaumard® Scientific to Showcase Trauma HAL, the Battlefield Trauma Patient Simulator, at I/ITSEC 2015

MIAMI, Nov. 30, 2015— Gaumard Scientific Company today announced it will showcase Trauma HAL® and Pedi HAL® at I/ITSEC 2015, set for Nov. 30 – Dec.READ MORE…

Sucampo Announces Webcast of Its Presentation at Piper Jaffray 27th Annual Healthcare Conference

ROCKVILLE, Md., Nov. 25, 2015 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP), a global biopharmaceutical company, today announced that itREAD MORE…

CYC065, Cyclacel’s Novel CDK2/9 Inhibitor, Prolongs Survival in MYCN-Addicted Neuroblastoma Models

BERKELEY HEIGHTS, N.J., Nov. 23, 2015 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (“Cyclacel” or the “Company”), today announcedREAD MORE…

Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in December 2015

NORWOOD, MA — (Marketwired) — 11/23/15 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stageREAD MORE…

Cynapsus Therapeutics Expands Senior Leadership Team

TORONTO, Nov. 19, 2015 (GLOBE NEWSWIRE) — Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH), a specialty CNS pharmaceutical company developing and preparingREAD MORE…

PTC Completes Enrollment of Phase 3 Clinical Trial of Translarna™ for Patients with Cystic Fibrosis

SOUTH PLAINFIELD, N.J., Nov. 19,  2015 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has completed enrollment ofREAD MORE…

StemCells, Inc. Interim Trial Data Show Motor Improvement in Patients With Cervical Spinal Cord Injury

NEWARK, Calif., Nov. 18, 2015 (GLOBE NEWSWIRE) — StemCells, Inc.(NASDAQ:STEM), a world leader in the research and development of cell-basedREAD MORE…

BIND Therapeutics Announces Initiation of Clinical Studies with Accurin AZD2811 in Solid Tumors

CAMBRIDGE, Mass.–(BUSINESS WIRE)– BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins™, todayREAD MORE…

Sutro Biopharma Receives the Pantheon 2015 DiNA Outstanding Partner Award by the California Life Sciences Association

SAN FRANCISCO, Nov. 18, 2015 /PRNewswire/ — Sutro Biopharma today announced that it was awarded the Outstanding Partner Award, at theREAD MORE…

Symic Biomedical Selects Osteoarthritis Clinical Candidate

SAN FRANCISCO, Nov. 17, 2015​– Symic Biomedical, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellularREAD MORE…

Conatus Pharmaceuticals Announces Late-Breaking Oral Presentation at AASLD Annual Meeting

SAN DIEGO, Nov. 16, 2015 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today the delivery of a late-breaking oralREAD MORE…

Novavax to Make Multiple Presentations at RSV Vaccines for the World

GAITHERSBURG, Md., Nov. 16, 2015 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, developmentREAD MORE…

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, presented data from a PhaseREAD MORE…

Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting

SAN DIEGO, Nov. 16, 2015 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today the presentation of two posters, bothREAD MORE…

Conatus Pharmaceuticals Announces Selection of Late-Breaking Oral Presentation as Noteworthy Abstract to be Highlighted in AASLD President’s Press Conference at AASLD Annual Meeting

SAN DIEGO, Nov. 14, 2015 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today that the company’s late-breaking oral presentationREAD MORE…

Arrowhead Presents Data Showing Robust Sustained Anti-viral Effects with ARC-520 in Hepatitis B Infected Chimpanzees

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, presents data at the AASLDREAD MORE…

International Stem Cell Corporation Announces Operating Results for the Three- and Nine-Months Ended September 30, 2015

CARLSBAD, CA–(Marketwired – November 16, 2015) – International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) (“ISCO” or “the Company”), a California-basedREAD MORE…

Cyclacel Pharmaceuticals Reports Third Quarter 2015 Financial Results

Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (“Cyclacel” or the “Company”), a biopharmaceutical company developing oral therapies that target the various phasesREAD MORE…

Cynapsus Reports Third Quarter 2015 Financial Results and Recent Developments

Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH) (“Cynapsus” or the “Company”), a specialty central nervous system (“CNS”) pharmaceutical company developingREAD MORE…

Clinical Trial Results Disclosure by Large Biopharmaceutical Companies Falls Below Legal and Ethical Standards, Study Published in BMJ Open Shows

Bioethics International, a not-for-profit organization focused on the ethics and governance of how medicines are researched, developed, marketed and madeREAD MORE…

StemCells, Inc. Announces Webcast to Discuss Interim Results From the First Cohort in Its Phase II Study in Cervical Spinal Cord Injury

StemCells, Inc.(NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of theREAD MORE…

Arrowhead to Present at Upcoming Conferences

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the company will make presentationsREAD MORE…

Conatus Pharmaceuticals to Present at Stifel 2015 Healthcare Conference

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its scheduled presentation to provide an overview of the company’s programs and outlook atREAD MORE…

Corbus Pharmaceuticals Reports 2015 Third Quarter Financial Results

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, andREAD MORE…

BIND Therapeutics to Present at 2015 Stifel Healthcare Conference

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called AccurinsTM, today announced that AndrewREAD MORE…

Novavax to Present at the Stifel 2015 Healthcare Conference

Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants,READ MORE…

Astellas to Acquire Ocata Therapeutics

Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas“) and Ocata Therapeutics, Inc. (NASDAQ: OCAT, President and CEO:READ MORE…

Cellular Dynamics Announces Collaboration with Roche

Cellular Dynamics International, Inc. (CDI), a FUJIFILM company, today announced an agreement with Roche to supply CDI’s induced pluripotent stemREAD MORE…

Puma Biotechnology Reports Third Quarter 2015 Financial Results

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30,READ MORE…

PTC Therapeutics Reports Third Quarter 2015 Financial Results, Provides Corporate Update and Reviews Key Findings from ACT DMD

SOUTH PLAINFIELD, N.J., Nov. 9, 2015 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financialREAD MORE…

BIND Presents Data Demonstrating Ability of Accurins to Improve Efficacy and Tolerability of Multiple Anti-Cancer Agents

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins™, today reported data demonstratingREAD MORE…

Mechanistic Rationale for CYC065, Cyclacel’s CDK2/9 Inhibitor, in Targeted Solid Tumors and Hematological Malignancies Presented at AACR-NCI-EORTC International Conference

Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (“Cyclacel” or the “Company”), today announced the presentation of preclinical data demonstrating the mechanistic rationaleREAD MORE…

Novavax Reports Third Quarter 2015 Financial Results

Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants,READ MORE…

Novavax Initiates Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults

Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants,READ MORE…

Innovative and Realistic Gaumard Adult, Pediatric and Neonatal Simulators to be Showcased at the American Heart Association Scientific Sessions 2015

MIAMI, Nov. 6, 2015— Gaumard® Scientific Company today announced that it will provide demonstrations of its innovative HAL patient simulators and Newborn ToryREAD MORE…

Symic Biomedical Appoints Kamal Egodage, Ph.D., MBA, VP of Development & Manufacturing and Grace Wong-Sarad, VP and Controller

SAN FRANCISCO, Nov. 5, 2015​– Symic Biomedical, a clinical-stage biotherapeutics company developing multiple compounds that target the extracellular matrix (ECM),READ MORE…

Puma Biotechnology to Present at Credit Suisse Healthcare Conference

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief ExecutiveREAD MORE…

Alder BioPharmaceuticals to Present at the Credit Suisse 24th Annual Healthcare Conference

BOTHELL, Wash., November 3, 2015 – Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics forREAD MORE…

International Stem Cell Corporation Moves Forward With Parkinson’s Disease Clinical Trials in Australia

CARLSBAD, CA–(Marketwired – November 03, 2015) – International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stemREAD MORE…

Curis Announces Presentation of Preclinical Data From Small Molecule PD-L1/VISTA and IRAK4 Programs at the AACR-NCI-EORTC International Conference

LEXINGTON, Mass., Nov. 2, 2015 (GLOBE NEWSWIRE) — Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

PTC Therapeutics Announces Launch of STRIVE Grant Award Program for Cystic Fibrosis

SOUTH PLAINFIELD, N.J., Oct. 29, 2015 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the expansion of its StrategiesREAD MORE…

Catalyst Pharmaceuticals Announces Poster Presentation at 62nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry

CORAL GABLES, Fla., Oct. 27, 2015 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing andREAD MORE…

Symic Biomedical Advances First Product Candidate, SB-030, into Clinical Development with Treatment of First Patient in SHIELD Trial

SAN FRANCISCO, Oct. 27, 2015 – Symic Biomedical, a clinical‐stage biotherapeutics platform company developing compounds that target the extracellular matrixREAD MORE…

BIND Therapeutics’ Presentations at Upcoming AACR-NCI-EORTC Conference Reinforce Potential of Accurin Platform to Develop Best-in-Class Therapeutics

CAMBRIDGE, Mass.–(BUSINESS WIRE)– BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins™, todayREAD MORE…

Gaumard Patient Simulators to be Featured in Real-World Emergency Medical Training Scenarios at 2015 ACEP Scientific Sessions

MIAMI, Oct. 23, 2015 – Gaumard® Scientific Company today announced that it will demonstrate its innovative patient simulators at theREAD MORE…

Novavax Initiates Phase 2 Safety and Immunogenicity Trial to Evaluate Annual Re-Dosing of the RSV F Vaccine in Older Adults

GAITHERSBURG, Md., Oct. 22, 2015 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, developmentREAD MORE…

Cyclacel Doses First Patient in Phase 1 Trial of Its Novel CDK2/9 Inhibitor, CYC065, for the Treatment of Advanced Solid Tumors

BERKELEY HEIGHTS, N.J., Oct. 22, 2015 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a biopharmaceuticalREAD MORE…

Arrowhead Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2015

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that additional clinicalREAD MORE…

Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting

SAN DIEGO, Oct. 20, 2015 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today that a late-breaking abstract detailing resultsREAD MORE…

Novira Therapeutics to Present at 2015 AASLD Meeting in San Francisco

DOYLESTOWN, Pa., Oct. 20, 2015 /PRNewswire/ — Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing novel therapies for curativeREAD MORE…

Corbus Pharmaceuticals Announces FDA Orphan Drug Designation and Fast Track Status of Resunab(TM) for the Treatment of Cystic Fibrosis

NORWOOD, MA — (Marketwired) — 10/20/15 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stageREAD MORE…

Curis Expands Cancer Drug Pipeline With Small Molecule PD-L1/ VISTA Immune Checkpoint Antagonist and IRAK4 Kinase Inhibitors

LEXINGTON, Mass., Oct. 19, 2015 (GLOBE NEWSWIRE) — Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercializationREAD MORE…

Gaumard’s Latest UNI Operating System Is Compliant with Newly Released 2015 AHA CPR/ECC Guidelines

MIAMI, Oct. 16, 2015 /PRNewswire/ — Gaumard® Scientific Company today announced its latest update to the UNI® operating system. UNI Version 2.28.22.0 adds enhancedREAD MORE…

PTC Announces Results from Phase 3 ACT DMD Clinical Trial of Translarna™ (ataluren) in Patients with Duchenne Muscular Dystrophy

SOUTH PLAINFIELD, N.J., Oct. 15, 2015 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced results from the Phase 3,READ MORE…

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of Resunab(TM) for Treatment of Cystic Fibrosis

NORWOOD, MA — (Marketwired) — 10/15/15 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stageREAD MORE…

Arrowhead Presents Overview of Its Broad RNAi Delivery Platform and Introduces New Subcutaneously Administered Format

Oct 14, 2015 Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today presented an overview ofREAD MORE…

Veloxis etablerer sponsoreret Niveau 1 ADR program i U.S.A.

Veloxis Pharmaceuticals A/S (OMX: VELO)  har i dag offentliggjort etableringen af et sponsoreret Niveau 1 American Depositary Receipt(ADR) program iREAD MORE…

Sucampo Announces Results of Tender Offer for R-Tech Ueno

BETHESDA, Md., Oct. 14, 2015 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced theREAD MORE…

International Stem Cell Corporation Presents Comprehensive Findings for Parkinson’s Disease Program Preclinical Studies at the Society for Neuroscience Annual Meeting, Neuroscience 2015

CARLSBAD, CA–(Marketwired – October 14, 2015) – International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stemREAD MORE…

Apogenix to Present at Three Upcoming International Conferences

Heidelberg, Germany, Oct. 13, 2015 – Apogenix, a next generation immuno-oncology company, announced today that Chief Executive Officer Thomas Hoeger,READ MORE…

Alder BioPharmaceuticals Initiates Pivotal Clinical Trial of ALD403 for Preventative Treatment of Frequent Episodic Migraine

BOTHELL, Wash., Oct. 13, 2015 – Alder BioPharmaceuticals, Inc. (“Alder”) (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeuticsREAD MORE…

Corbus Pharmaceuticals to Present at the 14th Annual BIO Investor Forum

Presentation With Live Webcast on October 21, 2015 at 11:30 a.m. PDT / 2:30 p.m. EDT NORWOOD, MA — (Marketwired)READ MORE…

Timothy P. Walbert Joins Sucampo’s Board of Directors

BETHESDA, Md., Oct. 13, 2015 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced thatREAD MORE…

The Vancouver Sun: Lifelike manikin gives birth

She blinks, breathes, bleeds and births a baby, either by caesarean section or vaginally; take your pick. Victoria is aREAD MORE…

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of Resunab for Systemic Sclerosis

NORWOOD, MA — (Marketwired) — 10/07/15 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stageREAD MORE…

Forbes: Company Run By 30-Year-Old Former Hedge Fund Manager Starts Study To Get Its Alzheimer’s Drug Approved

Matthew Herper Oct 6, 2015 Axovant Sciences, the Alzheimer’s startup founded by former hedge fund manager Vivek Ramaswamy, announced thisREAD MORE…

Catalyst Pharmaceuticals Announces a Clinical Trial for Pediatric Patients With Congenital Myasthenic Syndromes

CORAL GABLES, Fla., Oct. 06, 2015 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing andREAD MORE…

Oncobiologics Announces ONS-1045 (Avastin®/bevacizumab biosimilar) Meets Primary and Secondary Endpoints in Phase 1 Clinical Trial

CRANBURY, N.J., Oct. 5, 2015 /PRNewswire/ — Oncobiologics, Inc. (“Oncobiologics”) announced that its bevacizumab (Avastin®) biosimilar candidate, ONS-1045, met the primary and secondaryREAD MORE…

Gaumard Scientific to Feature Comprehensive Line-Up of Innovative Patient Simulators for Health Care Education at the FIGO World Congress 2015

MIAMI, Oct. 2, 2015 — Gaumard® Scientific Company today unveiled its comprehensive line-up of innovative patient simulators that will be featured at The International FederationREAD MORE…

Conatus Pharmaceuticals Announces Acceptance of Abstracts for AASLD Annual Meeting

SAN DIEGO, Oct. 1, 2015 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today that abstracts for two posters addressingREAD MORE…

NIH Awards $1.7 Million Grant for Celdara Medical and Pulmatrix to Develop an Inhaled Biologic Treatment for Idiopathic Pulmonary Fibrosis

LEBANON, N.H., and LEXINGTON, Mass., Oct. 1, 2015 /PRNewswire/ — Celdara Medical, LLC and Pulmatrix, Inc. (NASDAQ: PULM) today announced that theREAD MORE…

Alder BioPharmaceuticals Appoints Paul R. Carter to Board of Directors

BOTHELL, Wash., Sept.30, 2015 – Alder BioPharmaceuticals, Inc. (“Alder”) (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics forREAD MORE…

International Stem Cell Corporation Develops Technology to Replace Cartilage for the Treatment of Osteoarthritis

CARLSBAD, CA–(Marketwired – September 30, 2015) – International Stem Cell Corporation (OTCQB: ISCO)(www.internationalstemcell.com, ISCO or the Company), a California-based biotechnologyREAD MORE…

Novavax Announces Positive Top-Line Data From RSV F Vaccine Phase 1 Clinical Trial in Pediatrics

GAITHERSBURG, Md., Sept. 29, 2015 (GLOBE NEWSWIRE) — Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, developmentREAD MORE…

Novavax Announces Positive Top-Line Data from Phase 2 Clinical Trial of RSV F Vaccine to Protect Infants via Maternal Immunization

GAITHERSBURG, Md., Sept. 29, 2015 /PRNewswire/ — Novavax, Inc., (Nasdaq: NVAX) a clinical-stage vaccine company focused on the discovery, development andREAD MORE…

Immunexpress Appoints Dr. Bea Arnold to Board of Directors

SEATTLE, Sept. 29, 2015 – Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, todayREAD MORE…

Arrowhead Reports Peak Reduction in HBsAg of Up to 99% (1.9 log) After a Single Dose with Hepatitis B Candidate ARC-520 in Treatment Naïve Cohort of Phase 2a Study

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, is hosting an analyst dayREAD MORE…

Conatus Announces Top-line Results From Multicenter Phase 2 Portal Hypertension Clinical Trial in Patients With Liver Cirrhosis

SAN DIEGO, Sept. 23, 2015 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced that the company’s exploratory Phase 2READ MORE…

Ocata to Present at Ladenburg Thalmann 2015 Healthcare Conference

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of regenerative medicine, today announced that Paul K. Wotton,READ MORE…

New Study Data Show SEM Scanner Detects Pressure Ulcers 3.9 Days Ahead of Today’s Standard of Care

LOS ANGELES and MANCHESTER, England, Sept. 22, 2015 /PRNewswire/ — BBI, LLC, today announced that its SEM Scanner, a handheld deviceREAD MORE…

International Stem Cell Names Ms. Ebrahimi as Chief Financial Officer

CARLSBAD, CA–(Marketwired – September 22, 2015) – International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com, ISCO or the Company), a California-basedREAD MORE…

Canine Patients Treated with Ocata’s Hemangio-derived Mesenchymal Cells (HMC™) Achieve Remission in a Model of Crohn’s Disease

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of regenerative medicine, and its collaborators today reported inREAD MORE…

Veloxis Announces Publication of Phase III-b STRATO Study of Envarsus® XR Demonstrating Reduction in Hand Tremors Compared to Twice-Daily Tacrolimus in Kidney Transplant Patients

Veloxis Pharmaceuticals A/S (OMX: VELO) is announcing the publication of the Phase IIIb Switching STudy of Kidney TRansplant PAtients toREAD MORE…

Accera Joins Alzheimer’s Association Research Roundtable

BROOMFIELD, Colo., Sept. 21, 2015 /PRNewswire/ — Accera, Inc., a clinical-stage biotechnology company developing therapies for central nervous system disorders, announcedREAD MORE…

Accera Supports World Alzheimer’s Day

BROOMFIELD, Colo., Sept. 17, 2015 – Accera, Inc., a clinical-stage biotechnology company developing therapies for central nervous system disorders, announcedREAD MORE…

Cyclacel Presents Molecular Rationale for Clinical Development of CYC065 CDK Inhibitor in Leukemias and Lymphomas

BERKELEY HEIGHTS, N.J., Sept. 16, 2015 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (“Cyclacel” or the “Company”), today announced theREAD MORE…

Immunexpress to Present Data on SeptiCyte® at the “Meeting of Experts on Biomarkers to Discriminate Bacterial from Other Infectious Causes of Acute Fever”

SEATTLE, Sept. 16, 2015 –  Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, announcedREAD MORE…

Innocoll AG Announces First Patient Dosed in the XaraColl MATRIX-2 Phase 3 Study for the Treatment of Postoperative Pain

ATHLONE, Ireland, Sept. 16, 2015 (GLOBE NEWSWIRE) — Innocoll AG (NASDAQ:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufacturesREAD MORE…

Novavax RSV F Vaccine is Highly Immunogenic With Robust Transplacental Antibody Transfer in Preclinical Maternal Immunization Model

GAITHERSBURG, Md., Sept. 15, 2015 (GLOBE NEWSWIRE) — Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, developmentREAD MORE…

Pulmatrix to Highlight PUR1900 Data at 2015 North American Cystic Fibrosis Conference

LEXINGTON, Mass., Sept. 11, 2015 /PRNewswire/ — Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease,READ MORE…

Arrowhead Nominates ARC-HIF2 As First RNAi Therapeutic Candidate Using Extrahepatic DPC(TM) Delivery System

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it hasREAD MORE…

Novavax RSV F Vaccine Clinical Trial Data in Women of Child Bearing Age Published in the Journal of Infectious Disease

GAITHERSBURG, Md., Sept. 10, 2015 (GLOBE NEWSWIRE) — Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, developmentREAD MORE…

Arrowhead to Webcast Analyst Day Presentation on Hepatitis B Candidate ARC-520

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it willREAD MORE…

Gaumard to Unveil Entirely New HAL S315 Multipurpose Airway and CPR Skill Trainer Family at EMS World Expo

LAS VEGAS, Sept. 10, 2015 Gaumard (R) Scientific Company today announced that it will launch an entirely new and comprehensive HAL® S315 family ofREAD MORE…

Catalyst Pharmaceuticals Announces Intent to Develop a Generic Equivalent of Sabril

CORAL GABLES, Fla., Sept. 09, 2015 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing andREAD MORE…

Alder BioPharmaceuticals to Present at Morgan Stanley Global Healthcare Conference

BOTHELL, Wash., September 9, 2015 – Alder BioPharmaceuticals, Inc. (“Alder”) (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeuticsREAD MORE…

International Stem Cell Corporation Announces Next Phase of Research Collaboration With Rohto Pharmaceutical Co., Ltd. of Japan

CARLSBAD, CA–(Marketwired – September 08, 2015) – International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com, ISCO or the Company), a California-basedREAD MORE…

First Patient Enrolled in Ocata Therapeutics’ Phase 2 Study for Dry AMD

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that the first patientREAD MORE…

Pulmatrix to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2015

LEXINGTON, Mass., Sept. 3, 2015 /PRNewswire/ — Pulmatrix, Inc., (NASDAQ: PULM) will present at the Rodman & Renshaw 17thAnnual Global InvestmentREAD MORE…

Arena Pharmaceuticals to Present at the Wells Fargo 2015 Healthcare Conference

SAN DIEGO, Sept. 3, 2015 /PRNewswire/ — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present aREAD MORE…

Cyclacel Pharmaceuticals to Present at Rodman & Renshaw 17th Annual Global Investment Conference

BERKELEY HEIGHTS, N.J., Sept. 3, 2015 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (“Cyclacel” or the “Company”), a biopharmaceuticalREAD MORE…

Dr. Robert Lanza, Chief Scientific Officer of Ocata Therapeutics Awarded the Honor of iPSC Industry Influencer

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that Dr. Robert Lanza,READ MORE…

Novavax to Participate in Multiple Investor Conferences in September

GAITHERSBURG, Md., Sept. 02, 2015 (GLOBE NEWSWIRE) — Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, developmentREAD MORE…

Cynapsus Therapeutics Enrolls First Patient in Pivotal Phase 3 Safety Study of APL-130277 for the Treatment of OFF Episodes in Patients With Parkinson’s Disease

TORONTO, Sept. 2, 2015 (GLOBE NEWSWIRE) — Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH) (the “Company”) today announced enrollment of the firstREAD MORE…

CombiMatrix to Present at Rodman & Renshaw Global Investment Conference

IRVINE, Calif., Sept. 2, 2015 (GLOBE NEWSWIRE) — CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing servicesREAD MORE…

Alder BioPharmaceuticals to Present at Wells Fargo 2015 Healthcare Conference

BOTHELL, Wash., September 2, 2015 – Alder BioPharmaceuticals, Inc. (“Alder”) (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeuticsREAD MORE…

Innocoll AG Announces First Patient Dosed in the XaraColl MATRIX-1 Phase 3 Study for the Treatment of Postoperative Pain

ATHLONE, Ireland, Sept. 2, 2015 (GLOBE NEWSWIRE) — Innocoll AG (NASDAQ:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufacturesREAD MORE…

Ocata Therapeutics Receives SBIR Grant from the NIH’s National Eye Institute to Develop Proprietary Photoreceptor Progenitor Cell Therapy for Retinitis Pigmentosa

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that it has beenREAD MORE…

International Stem Cell Corporation to Present at the Rodman and Renshaw Global Investment Conference

CARLSBAD, CA–(Marketwired – September 01, 2015) – International Stem Cell Corporation (OTCQB: ISCO)(www.internationalstemcell.com, ISCO or the Company), a California-based biotechnologyREAD MORE…

Ocata Therapeutics Appoints Dr. Brian Levy to its Board of Directors

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that Brian Levy, O.D.,READ MORE…

SUCAMPO LAUNCHES TENDER OFFER TO ACQUIRE R-TECH UENO

BETHESDA, Md., Aug. 26, 2015 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) today announced the launch of an all-cash tenderREAD MORE…

StemCells, Inc. to Participate at the Rodman & Renshaw 17th Annual Global Investment Conference

NEWARK, Calif., Aug. 26, 2015 (GLOBE NEWSWIRE) — StemCells, Inc.(Nasdaq:STEM) announced today that management will make a presentation on theREAD MORE…

Ocata Therapeutics Receives SBIR Grant from NIH to Develop Proprietary Hemangio-derived Mesenchymal Cell Therapy for Lupus Nephritis

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that it has beenREAD MORE…

Alder BioPharmaceuticals Appoints Paul B. Cleveland to Board of Directors

BOTHELL, Wash., Aug. 20, 2015 – Alder BioPharmaceuticals, Inc. (“Alder”) (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeuticsREAD MORE…

Boston Business Journal: Norwood biotech’s shares soar on FDA news that could speed up drug approval

Don Seiffert Aug 19, 2015 Shares of Corbus Pharmaceuticals rose more than 50 percent today after the Norwood company announcedREAD MORE…

Ocata Therapeutics Secures $10 Million in Debt Financing

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that it hasREAD MORE…

Boston Business Journal: CEO of Marlborough biotech Ocata: ‘Our job is to own the eye’

Age-related macular degeneration is the leading cause of blindness in older Americans, so it’s no real surprise that Ocata TherapeuticsREAD MORE…

Catalyst Pharmaceuticals Appoints Paul J. Merrigan as Chief Commercial Officer

CORAL GABLES, Fla., Aug. 17, 2015 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializingREAD MORE…

High-fidelity simulation prepares future labor and delivery nurses to provide competent care

Advance for Nurses Danielle Bullen Aug 14, 2015 Every day, labor and delivery nurses help mothers welcome their new additionsREAD MORE…

Innocoll AG Appoints Rich Fante as Chief Commercial Officer and Head of Business Development

ATHLONE, Ireland, Aug. 13, 2015 (GLOBE NEWSWIRE) — Innocoll AG (NASDAQ:INNL) announced that Rich Fante has been appointed Chief CommercialREAD MORE…

GlobeImmune Engages Cantor Fitzgerald as Financial Advisor to Assist With Evaluation of Strategic Options

LOUISVILLE, CO–(Marketwired – August 13, 2015) – GlobeImmune, Inc. (NASDAQ: GBIM), a biopharmaceutical company focused on developing products for theREAD MORE…

Immunexpress to Present Data on the Early Diagnosis of Sepsis with SeptiCyte® Lab at the Next Generation Diagnostics Summit

SEATTLE, Aug. 12, 2015 –  Immunexpress, Inc. today announced that Dr. Therese Seldon, Vice President of Operations, will present dataREAD MORE…

Fierce Biotech: Adynxx eyes an IPO, late-stage program after pain drug clears a PhII hurdle

John Carroll Aug 11, 2015 Adynxx says that their second shot at statistically significant results in a mid-stage study forREAD MORE…

Novavax Announces Positive Top-Line Data from Phase 2 RSV F-Protein Vaccine Clinical Trial in Older Adults

Novavax, Inc. (Nasdaq: NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines andREAD MORE…

International Stem Cell Corporation Completes Clinical Testing of a New Compound

CARLSBAD, CA–(Marketwired – August 06, 2015) – International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stemREAD MORE…

Novavax to Present at the Wedbush PacGrow Healthcare Conference

GAITHERSBURG, Md., Aug. 05, 2015 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, developmentREAD MORE…

Arrowhead to Present at Jefferies 2015 Hepatitis B Summit

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation (NASDAQ: ARWR) today announced that chief operating officer and head of R&D Bruce Given,READ MORE…

Sutro Biopharma Appoints Nicki Vasquez, Ph.D. as VP of Alliance and Project Management

SAN FRANCISCO, Aug. 4, 2015 /PRNewswire/ — Sutro Biopharma today announced that it has appointed Nicki Vasquez, Ph.D., as vice presidentREAD MORE…

Catalyst Pharmaceuticals to Hold Second Quarter Financial Results Conference Call and Webcast on Tuesday, August 11th, 2015

CORAL GABLES, Fla., Aug. 04, 2015 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializingREAD MORE…

Novavax to Host Conference Call to Discuss Second Quarter Financial Results on August 10, 2015

GAITHERSBURG, Md., Aug. 03, 2015 (GLOBE NEWSWIRE) — Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, developmentREAD MORE…

International Stem Cell Corporation Submits Remaining Requested Safety Study Report for Clinical Trial Authorization

CARLSBAD, CA–(Marketwired – July 30, 2015) – International Stem Cell Corporation (ISCO), a California-based biotechnology company developing novel stem cellREAD MORE…

Sunshine Heart Provides Update on Fully Implantable Circulatory Support System

EDEN PRAIRIE, Minn., July 30, 2015 (GLOBE NEWSWIRE) — Sunshine Heart (NASDAQ:SSH) announced today an update on its next generation,READ MORE…

Gaumard’s Latest UNI Operating System Update Adds Performance and New Functionality

MIAMI, July 30, 2015 – Gaumard® Scientific Company today announced that the latest update to UNI®, the world’s first operatingREAD MORE…

Novavax Announces Positive Data From Phase 2 Trial of Quadrivalent Seasonal Influenza VLP

GAITHERSBURG, Md., July 30, 2015 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, developmentREAD MORE…

Arena Pharmaceuticals Initiates a Phase 2 Clinical Trial of APD334, its S1P1 Receptor Modulator for Autoimmune Diseases

SAN DIEGO, July 29, 2015 /PRNewswire/ — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of patient screening in aREAD MORE…

International Stem Cell Corporation Announces 1:150 Reverse Stock Split

CARLSBAD, CA–(Marketwired – July 28, 2015) – International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stemREAD MORE…

Apogenix Enters into Cooperation with R-Biopharm to Develop Companion Diagnostic Tests for Immuno-Oncology Candidate APG101

HEIDELBERG, Germany, July 28, 2015 /PRNewswire/ — Apogenix, a next generation immuno-oncology company, announced today that it has entered intoREAD MORE…

Sucampo Announces Second Quarter 2015 Earnings Call

BETHESDA, Md., July 22, 2015 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced thatREAD MORE…

StemCells, Inc. Announces Webcast to Discuss Second Quarter 2015 Financial Results

NEWARK, Calf., July 22, 2015 (GLOBE NEWSWIRE) — StemCells, Inc.(Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-basedREAD MORE…

Novavax Announces Positive Top-Line Data From Phase 1 Ebola Vaccine Trial on WHO Teleconference

GAITHERSBURG, Md., July 21, 2015 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, developmentREAD MORE…

The big gamble: Catalyst Pharmaceuticals of Coral Gables bets on new drug for rare disease

Miami Herald JOSEPH A. MANN JR. July 18, 2015 About six years ago, Lisa Rountree, 45, a mother of twoREAD MORE…

StemCells, Inc. Transplants First Patient in Phase II Clinical Trial for Dry Age-Related Macular Degeneration

NEWARK, Calif., July 20, 2015 (GLOBE NEWSWIRE) — StemCells, Inc.(Nasdaq:STEM), a world leader in the research and development of cell-basedREAD MORE…

SiteOne Therapeutics Secures Investment from Bozeman-based Next Frontier Capital

BOZEMAN, MONTANA, July 15, 2015 — SiteOne Therapeutics Inc. today announced the completion of an investment by Next Frontier Capital,READ MORE…

Apogenix Enters into Licensing Agreement with CANbridge Life Sciences for Immuno-Oncology Candidate APG101 in China

Heidelberg, Germany, July 15, 2015 – Apogenix, a next generation immuno-oncology company, announced today that it has entered into anREAD MORE…

Ocata Therapeutics Receives New U.S. Patent for Its RPE Therapy for Macular Degenerative Diseases

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that it continues toREAD MORE…

Accera Reaches 75% Enrollment in the Phase 3 NOURISH AD Study of AC-1204 for the Treatment of Alzheimer’s Disease

BROOMFIELD, Colo., July 14, 2015 /PRNewswire/ – Accera, Inc. today announced that it has achieved 75% enrollment for its NOURISH AD Phase 3 clinicalREAD MORE…

Ocata Therapeutics Announces New Pre-Clinical Data to be Reported at the International Congress on Systemic Lupus Erythematosus

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ:OCAT), a leader in the field of Regenerative OphthalmologyTM, announced today thatREAD MORE…

Corbus Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Resunab(TM) for the Treatment of Dermatomyositis

NORWOOD, MA — (Marketwired) — 07/13/15 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stageREAD MORE…

Arrowhead Receives Regulatory Clearance for ARC-AAT Phase 1 in the United Kingdom and New Zealand

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it receivedREAD MORE…

Cempra Completes Patient Enrollment of Solitaire-IV Phase 3 Clinical Trial

CHAPEL HILL, N.C., July 7, 2015 (GLOBE NEWSWIRE) — Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibioticsREAD MORE…

First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing’s Disease, a Serious Endocrine Disorder

BERKELEY HEIGHTS, N.J., July 2, 2015 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a biopharmaceuticalREAD MORE…

Arrowhead Initiates Dosing of ARC-AAT in Patients with Alpha-1 Antitrypsin Deficiency

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it dosedREAD MORE…

StemCells, Inc. to Participate at Cantor Fitzgerald’s Inaugural Healthcare Conference

NEWARK, Calif., July 1, 2015 (GLOBE NEWSWIRE) — StemCells, Inc.(Nasdaq:STEM) announced today that management will make a presentation on theREAD MORE…

Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product

AURORA, Colo. and BANGALORE, India, July 1, 2015 – Strand Life Sciences, a global genomic profiling company that uses nextREAD MORE…

Pharnext’s PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting

PARIS, June 30, 2015, Pharnext SAS today announced that data related to its lead pleodrug PXT-3003, being developed for theREAD MORE…

Catalyst Pharmaceuticals Appoints Dr. Gary Ingenito as Chief Medical Officer

CORAL GABLES, Fla., June 30, 2015 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing andREAD MORE…

Innocoll AG Announces Qualified Infectious Disease Product (QIDP) Designation for Cogenzia for the Adjunctive Treatment of Moderate and Severe Diabetic Foot Infection

ATHLONE, Ireland, June 30, 2015 (GLOBE NEWSWIRE) — Innocoll AG (NASDAQ:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufacturesREAD MORE…

Ocata Therapeutics Added to Russell 2000, 3000, Global and Microcap Indices

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ:OCAT), a leader in the field of Regenerative Ophthalmology™, announced today that theREAD MORE…

Catalyst Pharmaceuticals Joins Russell 2000, 3000 and Global Indexes

CORAL GABLES, Fla., June 29, 2015 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing andREAD MORE…

Cyclacel & ManRos Therapeutics Announce Licensing & Supply Agreement Regarding Development of Seliciclib in Cystic Fibrosis

DUNDEE, UK and ROSCOFF, France, June 29, 2015 (GLOBE NEWSWIRE) — Cyclacel Ltd, a wholly owned subsidiary of Cyclacel Pharmaceuticals,READ MORE…

StemCells, Inc. Reports Top Line Results for Its Phase I/II Study in Dry Age Related Macular Degeneration

NEWARK, Calif., June 26, 2015 (GLOBE NEWSWIRE) — StemCells, Inc.(NASDAQ:STEM), a leading stem cell company developing novel cell-based therapeutics forREAD MORE…

Conatus Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial of Emricasan Confirming Activity of Relevant Mechanisms and Opportunity for Histological Improvement

SAN DIEGO, June 25, 2015 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced pre-treatment biomarker and histology data fromREAD MORE…

Cynapsus Therapeutics’ APL-130277 Improved Parkinson’s Symptoms and Rapidly Turned Patients from OFF to ON in Data Presented at the International Congress of Parkinson’s Disease and Movement Disorders

TORONTO – (Marketwired) – Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH) (the “Company”) today announced that it presented data fromREAD MORE…

CombiMatrix Expands Sales Team to Accelerate Entry Into New Markets

IRVINE, Calif., June 25, 2015 (GLOBE NEWSWIRE) — CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based diagnostic servicesREAD MORE…

Catalyst Pharmaceuticals Announces Encouraging Top-Line Results in Proof-of-Concept Trial of Vigabatrin in Patients With Treatment-Refractory Tourette’s Disorder

CORAL GABLES, Fla., June 24, 2015 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing andREAD MORE…

Ocata Therapeutics Announces Positive Results Reported in a Late Breaking Abstract at the Annual Meeting of the International Society for Stem Cell Research

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, announced today thatREAD MORE…

Accera Pivots From Medical Foods to Potential Drug for Alzheimer’s

The war against Alzheimer’s disease has been a brutal, losing fight. Those stricken with the disease, their loved ones, andREAD MORE…

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

CALGARY, June 22, 2015 /CNW/ – Resverlogix Corp. (TSX: RVX) today announced that following recent meetings with various European regulatory bodies,READ MORE…

Biotech convo: A look ahead

This year’s Biotechnology Industry Organization’s convention in Philadelphia was on familiar ground for Joe Panetta, CEO of San Diego-based Biocom,READ MORE…

NOVAVAX RECOGNIZED BY WASHINGTON POST AS TOP WORKPLACE

GAITHERSBURG, Md., June 19, 2015 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, developmentREAD MORE…

Ocata Therapeutics to Ring the NASDAQ Stock Market Opening Bell on June 24, 2015

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that CompanyREAD MORE…

NOVAVAX APPOINTS GAIL BOUDREAUX TO BOARD

GAITHERSBURG, Md., June 18, 2015 (GLOBE NEWSWIRE) — Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, developmentREAD MORE…

StemCells, Inc.’s Phase II Pathway Study for Cervical Spinal Cord Injury Approved by Health Canada

NEWARK, Calif., June 18, 2015 (GLOBE NEWSWIRE) — StemCells, Inc.(Nasdaq:STEM), a world leader in the research and development of cell-basedREAD MORE…

UT San Diego: San Diego biotech visits Philly

Bradley Fikes June 17, 2015 I wasn’t able to attend this year’s Biotechnology Industry Organization convention this year. But othersREAD MORE…

Boston Herald: Norwood company tests immune reset drug

A Norwood pharmaceutical company is launching three phase-two studies this summer to test a medication for illnesses that cause debilitatingREAD MORE…

Arrowhead Receives Regulatory Clearance to Begin Additional Phase 2b Studies of Hepatitis B Candidate ARC-520

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that its ClinicalREAD MORE…

HIGH-TECH MANIKIN GIVES STUDENTS HANDS-ON TRAINING IN CHILDBIRTH

LOS ANGELES (KABC) –A high-tech true-to-life manikin mother is about to deliver a baby and ABC7 health specialist Denise DadorREAD MORE…

CHINA FOOD AND DRUG ADMINISTRATION ACCEPTS IND FOR PIVOTAL STUDY OF AMITIZA(R) (LUBIPROSTONE)

BETHESDA, Md., June 15, 2015 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global pharmaceutical company, today announced thatREAD MORE…

NOVAVAX ANNOUNCES MANAGEMENT PROMOTION

GAITHERSBURG, Md., June 15, 2015 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, developmentREAD MORE…

Innocoll AG Announces First Patient Dosed in the Cogenzia COACT-2 Phase 3 Study for the Treatment of Diabetic Foot Infection

ATHLONE, Ireland, June 15, 2015 (GLOBE NEWSWIRE) — Innocoll AG (Nasdaq:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range ofREAD MORE…

Arrowhead Receives Orphan Drug Designation for ARC-AAT

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced the United StatesREAD MORE…

GlobeImmune Announces Evaluation of Strategic Alternatives and Corporate Restructuring

LOUISVILLE, CO–(Marketwired – June 10, 2015) – GlobeImmune, Inc. (NASDAQ: GBIM) today announced that it is evaluating strategic options forREAD MORE…

Gaumard to Offer Preview of Newborn Tory at INACSL Alongside Demonstrations of Victoria and Gaumard’s Comprehensive Family of Patient Simulators

MIAMI, June 9, 2015 /PRNewswire/ — Gaumard (R) Scientific Company today announced that it will offer a preview of NewbornREAD MORE…

Gaumard Scientific to Launch Industry’s Most Advanced Newborn Simulator, Newborn Tory, at AWHONN 2015 Convention

MIAMI, June 8, 2015 – Gaumard® Scientific Company today announced that it will launch Newborn Tory (TM) S2210, the industry’s mostREAD MORE…

Resverlogix Reports on the Beneficial Effects of RVX-208 on Glucose Metabolism in Prediabetes Mellitus at the American Diabetes Association’s (ADA) Scientific Sessions in Boston, MA

CALGARY, June 8, 2015 /CNW/ – Resverlogix Corp. (TSX: RVX) today announced that findings of a study performed by theREAD MORE…

Corbus Pharmaceuticals Expands Clinical Development of Resunab™ with a Phase 2 Trial for the Treatment of Rare Disease Dermatomyositis

NORWOOD, MA — (Marketwired) — 06/05/15 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stageREAD MORE…

StemCells, Inc. Announces Commencement of the Second Cohort of the Pathway(TM) Study in Cervical Spinal Cord Injury

NEWARK, Calif., June 4, 2015 (GLOBE NEWSWIRE) — StemCells, Inc.(Nasdaq:STEM), a world leader in the research and development of cell-basedREAD MORE…

Apogenix appoints Peter Willinger as new CFO

HEIDELBERG, Germany, June 3, 2015 /PRNewswire/ — Apogenix, a next generation immuno-oncology company, announced today the appointment of Peter Willinger asREAD MORE…

Ocata Therapeutics Receives Important New U.S. Patent for its RPE Therapy for Macular Degenerative Diseases

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that itREAD MORE…

Health Care Educators Continue to Select Gaumard Scientific’s Victoria as Preferred Birthing Simulator for Simulation Centers

MIAMI, June 1, 2015 /PRNewswire/ — Gaumard® Scientific Company (www.gaumard.com) today announced that its U.S. installations of the Victoria™ birthing simulatorREAD MORE…

Biospace: Corbus Will Interview Twice as Many Candidates in 2015 as Its Ranks Grow

Yuval Cohen is the chief executive officer of Corbus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focusing on rare, life-threatening,READ MORE…

Strand Life Sciences Set to Introduce Expanded StrandAdvantage Genomic Profiling Service at 2015 ASCO Annual Meeting

AURORA, Colo., May 27, 2015 – Strand Life Sciences, a global genomic profiling company that uses next generation sequencing technologyREAD MORE…

Sucampo Announces Webcast of Its Presentation at the Jefferies 2015 Healthcare Conference

BETHESDA, Md., May 27, 2015 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced thatREAD MORE…

GlobeImmune Announces Top Line Results From GS-4774 Phase 2 Trial in Virally-Suppressed Chronic HBV Patients

LOUISVILLE, CO–(Marketwired – May 27, 2015) – GlobeImmune, Inc. (NASDAQ: GBIM) today announced top line results from the GS-4774 PhaseREAD MORE…

Sunshine Heart Announces FDA Approval to Resume Enrollment in COUNTER HF(TM) US Pivotal Study for C-Pulse(R) Heart Assist System